JW Pharmaceutical's US Research Corporation Relocates to Boston CIC, the 'Bio Heart'

Boston Cambridge Innovation Center (CIC). [Photo by JW Pharmaceutical]

[Asia Economy Reporter Lee Gwan-joo] JW Pharmaceutical announced on the 23rd that its U.S. research subsidiary JW Theriac has relocated from San Diego to the Cambridge Innovation Center (CIC) in Boston.

JW Theriac is a chemical genomics specialized research institute established by JW Pharmaceutical in Seattle, USA, in 2000. Together with JW Pharmaceutical's domestic New Drug Research Center, it has been conducting innovative new drug research targeting the Wnt signaling pathway. In 2018, it moved to San Diego and has served as the forefront base for JW Group's "open innovation."

With the relocation of JW Theriac to Boston, JW Pharmaceutical plans to expand its network with the U.S. bio cluster and increase translational research in preclinical and clinical stages, as well as technology transfers, based on JW's research and development (R&D) capabilities. It also plans to gather market information on the global bio industry and explore new investment opportunities.

Boston is a global cluster in the bio field, home to global pharmaceutical companies, promising bio ventures, and world-renowned hospitals and research institutions. Over 1,000 pharmaceutical and bio companies worldwide have established bases in the Boston bio cluster, generating an economic effect exceeding 2 trillion dollars. The CIC, established in Boston in 1999, is known as the number one network hub for the biohealth industry.

Park Chan-hee, Chief Technology Officer (CTO) of JW Group, said, "Boston, the largest pharmaceutical market in the U.S., is the center leading the global pharmaceutical and bio industry and the optimal bio cluster with the best-established related industrial ecosystem. We expect JW Theriac to play a key role as a core base in executing our global open innovation strategy."

This content was produced with the assistance of AI translation services.